SEQUENCE LISTING

<110> JANSSEN BIOTECH, INC.

<120> COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS

<130> PRD3424WOPCT

<140>
<141>

<150> 62/422,738
<151> 2016-11-16

<150> EP 16197293.0
<151> 2016-11-04

<150> 62/370,018
<151> 2016-08-02

<160> 8

<170> PatentIn version 3.5

<210> 1
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 1
tagggttaga caa 13

<210> 2
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 2
taggtgtaag caa 13

<210> 3
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 3
aacagattgg gat 13

<210> 4
<211> 24

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 4
tgtactttgt caaggtggat gtga 24

<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 5
gctggaggtc tgtcaaggta gag 23

<210> 6
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic probe"

<400> 6
cgcgtacgac accat 15

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 7
aatccgtcga gcagagtt 18

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 8
gcgcggctta cccttaccct taccctaacc 30